Pomerantz Law Firm Launches Investigation into Corcept Therapeutics Investors Claims

Investigation into Corcept Therapeutics by Pomerantz Law Firm

Pomerantz Law Firm has initiated an investigation targeting investors of Corcept Therapeutics Incorporated, a company registered on the NASDAQ under the ticker symbol CORT. This inquiry arises from concerns surrounding possible securities fraud and illegal business practices involving the company's officials and directors.

The investigation follows a significant announcement made by Corcept on December 31, 2025. On that date, the company revealed that they had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application for relacorilant, which was intended to treat hypertension due to hypercortisolism. According to the press statement, while the FDA recognized the success of Corcept's pivotal GRACE trial, it deemed that further evidence was necessary to support an effective benefit-risk assessment for relacorilant.

This news had a drastic impact on Corcept's stock, which plummeted by $35.40 per share—an alarming 50.42% decline—falling to a closing price of $34.80 on the same day. This sharp drop has undoubtedly left investors unsettled and questioning the legitimacy of the information previously provided by the company.

As a result of these events, Pomerantz LLP, a law firm well-regarded for its expertise in corporate, securities, and antitrust class litigation, has reached out to those affected. They urge investors who feel they may be victims of Corcept's actions to get in touch with them for assistance. Lauren Peyton, a representative from the firm, is accessible at [email protected] and can be contacted directly at 646-581-9980, extension 7980.

Pomerantz LLP has been a mainstay in advocating for victims of securities fraud for over 85 years. Founded by Abraham L. Pomerantz, the firm holds a distinguished legacy in the landscape of class-action litigation, having secured numerous substantial settlements for class members affected by corporate misconduct, securities fraud, and breaches of fiduciary duty.

In light of this unfolding situation, impacted investors are encouraged to stay informed and consider their legal options. Pomerantz's investigation represents a significant opportunity for those who believe they have been misled or financially harmed by Corcept’s recent actions. The firm’s track record suggests a persistent dedication to making right the wrongs suffered by investors across various sectors.

To learn more about joining the class action or to receive additional information, interested individuals can visit Pomerantz Law Firm's website for more details. It’s crucial for investors to act promptly as timelines for legal actions can be time-sensitive and imperative in seeking justice against potential corporate malpractice.

In summary, the ongoing investigation by Pomerantz Law Firm into Corcept Therapeutics showcases the firm’s commitment to holding companies accountable and protecting the rights of investors amid troubling circumstances. As events continue to develop, keeping abreast of the latest information and seeking legal counsel, if necessary, will be vital for affected parties.